Previous Close | 1.1000 |
Open | 1.0500 |
Bid | 0.8000 |
Ask | 1.3500 |
Strike | 7.00 |
Expire Date | 2024-07-19 |
Day's Range | 1.0500 - 1.0500 |
Contract Range | N/A |
Volume | |
Open Interest | 301 |
MIAMI, June 27, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that Jeff Huber has been appointed to its Board of Directors, effective immediately.
Summit Therapeutics (SMMT) surges after data from a late-stage study shows that its experimental antibody beat Merck's Keytruda in a head-to-head setting in treating certain patients with lung cancer.
MIAMI, June 03, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that the Company received and accepted an unsolicited offer from an institutional investor to purchase 22,222,222 shares of the Company’s common stock at $9.00 per share, a premium to the closing price on Friday, May, 31, 2024, for aggregate gross proceeds to the Company of approximately $200.0 million.